Company / SG&A Expense
Sana Biotechnology, Inc. SG&A Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$64.0M
FY2024
5-year range
$28.3M / $73.3M
FY2020-FY2024
Trend
-12.6%
vs FY2023
Sector context
#139 of 213
Health Care
What the data says
At $64M, Sana Biotechnology, Inc.'s sg&a expense ranks #75 of 213 in the Health Care sector. Improved from $72M to $64M over the past 2 years.
Based on SEC 10-K filings.
$64M in FY2024 with a 5-year CAGR of +24.1%.
Improved from $72M to $64M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +8.3%
- 5-Year CAGR
- +24.1%
- 10-Year CAGR
- -
Sector benchmark
#75 of 213 in Health CareTop 35% of 213This company $64.0M Sector average $722.3M
▼
-91.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.1%, indicating consistent growth.
- In FY2024, sg&a expense decreased 12.6% year-over-year.
- Ranks #139 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $64.0M | -12.6% |
| FY2023 | $73.3M | +2.4% |
| FY2022 | $71.6M | +42.0% |
| FY2021 | $50.4M | +78.3% |
| FY2020 | $28.3M | +29.8% |
| FY2019 | $21.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026